Exelixis, Inc. — Form 10-K Summary
Period clarification: The request specifies “2020 Q4,” but the supplied filing is Exelixis’s Form 10-K for the fiscal year ended December 31, 2021. It compares full fiscal years 2021 and 2020; it does not provide a standalone Q4 summary.
Business context and reporting period
Exelixis is an oncology-focused biotechnology company. CABOMETYX and COMETRIQ, both containing cabozantinib, generated most of its revenue. During 2021, CABOMETYX gained U.S. approval for first-line advanced renal cell carcinoma (RCC) in combination with OPDIVO and for previously treated differentiated thyroid cancer (DTC). The company also advanced pipeline candidates XL092, XB002, XL102 and XL114. Fiscal 2021 and 2020 were each 52-week years.
Financial performance
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Total revenue | $1,435.0 million | $987.5 million | +45% |
| Net product revenue | $1,077.3 million | $741.6 million | +45% |
| License revenue | $250.0 million | $167.3 million | +49% |
| Collaboration services revenue | $107.8 million | $78.7 million | +37% |
| Operating expenses | $1,148.3 million | $877.5 million | +31% |
| Income from operations | $286.7 million | $110.1 million | — |
| Net income | $231.1 million | $111.8 million | — |
| Diluted EPS | $0.72 | $0.35 | — |
| Net cash from operating activities | $400.8 million | $209.0 million | — |
| Cash, cash equivalents and investments | $1,854.9 million | $1,538.8 million | +21% |
Gross margin was 95% in both years. Based on reported figures, operating margin was approximately 20% in 2021 versus 11% in 2020, and net margin approximately 16% versus 11%. Working capital was $1,497.2 million at year-end 2021, up 21%. Net cash used in investing activities was $42.9 million and net cash used in financing activities was $14.8 million. The balance sheet does not present borrowings as a separate liability; the filing text does not provide a clear debt total. Total liabilities were $405.6 million.
Material changes versus 2020
- Net CABOMETYX revenue rose 47% to $1,054.1 million, primarily on a 42% increase in units sold following the first-line RCC combination launch and a 3% increase in average net selling price. COMETRIQ revenue increased 2% to $23.2 million.
- License revenue included a $100.0 million Ipsen sales milestone. Collaboration services revenue benefited from Ipsen’s COSMIC-311 opt-in, including a $43.2 million cumulative catch-up for development cost reimbursements.
- R&D expense increased 27% to $693.7 million; SG&A increased 37% to $401.7 million. Higher pipeline, personnel and commercial-launch spending contributed to expense growth.
- Operating cash flow increased to $400.8 million, while cash and investments grew by $316.1 million. Trade receivables rose to $282.7 million from $160.9 million.
Outlook, commentary and risks
- Management expected 2022 net product revenue to increase, driven mainly by CABOMETYX growth; it projected R&D and SG&A expenses to rise, while license revenue and collaboration services revenue could decline versus 2021. The filing does not provide a numerical revenue or earnings guidance range.
- Management projected a 2022 effective tax rate of 20%–22% and expected gross margin to remain consistent with 2021.
- Major clinical catalysts included expected COSMIC-313 top-line results in the first half of 2022; COSMIC-312 final overall-survival analysis in the first quarter of 2022; and CONTACT-01 and CONTACT-03 analyses anticipated in the second half of 2022. These were forward-looking expectations, not reported outcomes.
- COSMIC-312 met its progression-free-survival endpoint in first-line HCC, reducing the risk of progression or death by 37% versus sorafenib; interim overall survival was not statistically significant. The trial continued to final OS analysis.
- Generic competition is a significant risk: MSN and Teva filed applications for generic CABOMETYX, and Exelixis was litigating patent claims. The company stated it could not predict the outcomes or timing; an early generic launch could materially reduce revenue.
- Other key risks include competitive treatment options, reimbursement and drug-pricing pressure, clinical or regulatory setbacks, dependence on Ipsen and Takeda for ex-U.S. commercialization, third-party manufacturing reliance, and potential COVID-19 effects on trials and operations.
- Exelixis reported no significant COVID-related supply-chain disruption or business interruption to date. The audited financial statements received an unqualified opinion, and the auditor reported effective internal control over financial reporting.
Important facts for investors to verify
- Confirm the intended reporting period: the supplied filing covers fiscal 2021, not 2020 Q4.
- Track CABOMETYX sales growth, discount and rebate rates, and the effect of the RCC and DTC launches on realized revenue.
- Review outcomes and timing of the HCC, RCC, NSCLC and prostate cancer trials, distinguishing interim findings from final results and regulatory submissions.
- Monitor MSN and Teva patent litigation, ANDA developments and any potential generic-entry dates.
- Assess whether rising R&D and SG&A spending, collaboration milestones and reimbursements translate into sustained operating cash flow and profitability.
- Review liquidity and long-term commitments, including the planned 220,000-square-foot facility lease, and confirm debt or financing obligations in the complete filing.